A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
Clinical trial NCT07446387 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07446387
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2028-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.